Showing papers by "Pauline Brice published in 2012"
Fox Chase Cancer Center1, Stanford University2, University of Paris3, Washington University in St. Louis4, University of Miami5, National Health Service6, Wayne State University7, University of Texas MD Anderson Cancer Center8, University of British Columbia9, Seattle Genetics10, University of Washington11
TL;DR: Targeted therapy with this CD30-directed antibody-drug conjugate brentuximab vedotin may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy.
Abstract: Purpose Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate brentuximab vedotin delivers the potent antimicrotubule agent monomethylauristatin E to CD30-positive malignant cells. A phase II multicenter trial was conducted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic ALCL. Patients and Methods Patients with systemic ALCL and recurrent disease after at least one prior therapy received brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks over 30 minutes as an outpatient infusion. The primary end point of the study was overall objective response rate as assessed by independent central review. Results Of 58 patients treated in the study, 50 patients (86%) achieved an objective response, 33 patients (57%) achieved a complete remission (CR), and 17 patients (29%) achieved a partial remission. The median durations of overall respons...
843 citations
TL;DR: PET performed either after four cycles of R-CHOP or at the end of therapy was strongly predictive of outcome in this prospective study and therapeutic intervention based on PET results during or after inductive treatment should be evaluated.
Abstract: Purpose [18F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with aggressive lymphoma, but less is known about the utility of PET in patients with follicular lymphoma (FL). In a prospective study, we evaluated the prognostic value of PET performed during treatment and at the end of treatment in 121 patients with FL treated with first-line immunochemotherapy. Patients and Methods Patients with previously untreated high–tumor burden FL were treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituximab, without rituximab maintenance. PET was performed before treatment, after four cycles of R-CHOP (interim PET), and at the end of treatment (final PET). PET scans were centrally reviewed. Results The total number of patients included was 121. Median age was 57 years. After central review, interim PET (n = 111) was negative in 76% of patients, and final PET (n = 106) was negativ...
167 citations
University Medical Center Groningen1, University of Caen Lower Normandy2, University of Antwerp3, University of Groningen4, Erasmus University Rotterdam5, Leiden University6, Institut Gustave Roussy7, Katholieke Universiteit Leuven8, university of lille9, Utrecht University10, Radboud University Nijmegen11, Drug Abuse Resistance Education12
TL;DR: Nonalkylating chemotherapy carries little to no excess risk of premature ovarian failure (POF) occurrence and motherhood, and dose-response relationships for alkylating chemotherapy and age at treatment are both linear.
Abstract: Purpose In this large cohort of Hodgkin’s lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment.
90 citations
TL;DR: The results of the first clinical trial targeting both the neoplastic T cells and the microenvironment-associated CD20+ B lymphocytes in angioimmunoblastic T-cell lymphoma are reported, showing no clear benefit of adding rituximab to conventional chemotherapy.
Abstract: Background In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20+ large B-blasts, often infected by Epstein-Barr virus, are found in tumor tissues. We postulated that the disruption of putative B-T interactions and/or depletion of the Epstein-Barr virus reservoir by an anti-CD20 monoclonal antibody (rituximab) could improve the clinical outcome produced by conventional chemotherapy.Design and Methods Twenty-five newly diagnosed patients were treated, in a phase II study, with eight cycles of rituximab + chemotherapy (R-CHOP21). Tumor infiltration, B-blasts and Epstein-Barr virus status in tumor tissue and peripheral blood were fully characterized at diagnosis and were correlated with clinical outcome.Results A complete response rate of 44% (95% CI, 24% to 65%) was observed. With a median follow-up of 24 months, the 2-year progression-free survival rate was 42% (95% CI, 22% to 61%) and overall survival rate was 62% (95% CI, 40% to 78%). The presence of Epstein-Barr virus DNA in peripheral blood mononuclear cells (14/21 patients) correlated with Epstein-Barr virus score in lymph nodes (P100 copy/μg DNA) was associated with shorter progression-free survival (P=0.06).Conclusions We report here the results of the first clinical trial targeting both the neoplastic T cells and the microenvironment-associated CD20+ B lymphocytes in angioimmunoblastic T-cell lymphoma, showing no clear benefit of adding rituximab to conventional chemotherapy. A strong relationship, not previously described, between circulating Epstein-Barr virus and circulating tumor cells is highlighted.
70 citations
TL;DR: Data indicate that FCGR3A and FCGR2A polymorphisms do not influence response rate and outcome when rituximab is combined with chemotherapy or used as maintenance treatment.
60 citations
TL;DR: Escalated BEACOPP and derivatives achieved superior time to treatment failure (FFTF) over COPP/ABVD, resulting in higher overall survival (OS) for advanced HL, however, later clinical trials have failed to confirm OS superiority over ABVD.
Abstract: 8002 Background: Escalated BEACOPP and derivatives achieved superior time to treatment failure (FFTF) over COPP/ABVD, resulting in higher overall survival (OS) for advanced HL. However, later clini...
52 citations
TL;DR: Whether chemotherapy alone is as effective as standard combined modality treatment in patients with an early PET negative status is evaluated and whether intensification of chemotherapy is more effective than standard chemotherapy in early PET positive patients is evaluated.
37 citations
TL;DR: Survivors of HL had slightly but significantly fewer children after treatment than matched general population controls and appears to have more personal than biologic reasons.
Abstract: Purpose We investigated the impact of Hodgkin lymphoma (HL) on parenthood, including factors influencing parenthood probability, by comparing long-term HL survivors with matched general population controls.
30 citations
TL;DR: A phase 2 study to investigate if patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma who have previously responded to brentuximab vedotin could achieve another remission with retreatment with success.
Abstract: 8027 Background: Brentuximab vedotin comprises an anti-CD30 antibody conjugated by a protease-cleavable linker to a microtubule-disrupting agent, MMAE. In pivotal phase 2 studies in patients (pts) with relapsed/refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL), objective response rates were 75% and 86% and median durations of response were 6.7 and 12.6 mo, respectively. A phase 2 study was initiated to investigate if pts who have previously responded to brentuximab vedotin could achieve another remission with retreatment (ClinicalTrials.gov #NCT00947856). Methods: Pts had a CD30-positive hematologic malignancy, achieved an objective response (per Cheson 2007) with prior brentuximab vedotin treatment, and experienced relapse after discontinuing treatment. Brentuximab vedotin was administered IV 1.8 mg/kg every 21 days; antitumor activity was assessed by the investigator. Results: 14 HL pts and 8 sALCL (5 ALK-negative) pts were enrolled (median age 34 yr, range 16–72). Pts ...
16 citations
TL;DR: A phase 2 study to determine the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory sALCL found that all subgroups of patients analyzed in the study achieved a similar level of antitumor activity regardless of baseline disease characteristics, tumor burden, or prior treatment history.
6 citations
TL;DR: The clinicopathological findings of 13 cHL arising in patients treated for a primary haematological malignancy are reported, finding most patients had disseminated disease with poor prognostic factors at cHL diagnosis.
Abstract: Summary The risk of developing Hodgkin lymphoma (HL) is increased in immunodeficiencies or during the treatment of some autoimmune diseases The development of new therapeutic agents has highlighted the risk of unusual lymphoid proliferations, particularly classical HL (cHL) We report the clinicopathological findings of 13 cHL arising in patients treated for a primary haematological malignancy Eight patients had received an immunomodulator, protein tyrosine-kinase inhibitor or monoclonal antibody, which may have contributed to the cHL development Most patients had disseminated disease with poor prognostic factors at cHL diagnosis Despite the initial presentation, good outcomes were achieved with standard cHL chemotherapy